Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and mendelian randomization study

<p>There is conflicting real-world evidence regarding the risk of breast and bladder cancer associated with sodium glucose cotransporter 2 (SGLT2) inhibitors. We conducted a pharmacovigilance study on SGLT2 inhibitors and breast and bladder cancer using the US FDA Adverse Event Reporting Syste...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bo Xu (233514) (author)
Otros Autores:	Tianqiao Zhang (22675400) (author), Yechuan He (22052186) (author), Aihua Jiang (3394685) (author), Yinglan Liu (8128521) (author), Zunbo He (19504945) (author), Jiecan Zhou (6517283) (author)
Publicado:	2025
Materias:	Medicine Physiology Pharmacology Biotechnology Sociology Immunology Cancer Biological Sciences not elsewhere classified Chemical Sciences not elsewhere classified SGLT2 inhibitors Aersmine FAERS bladder cancer breast cancer mendelian randomization
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and mendelian randomization study

Ejemplares similares